Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration.
Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group; Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group, et al. Among authors: bressler nm. Ophthalmology. 2007 Sep;114(9):1713-21. doi: 10.1016/j.ophtha.2007.03.071. Ophthalmology. 2007. PMID: 17822977 Clinical Trial.
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sickenberg M, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Saperstein DA, et al. Among authors: bressler nm. Ophthalmology. 2002 Aug;109(8):1499-505. doi: 10.1016/s0161-6420(02)01103-x. Ophthalmology. 2002. PMID: 12153802 Clinical Trial.
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Blumenkranz MS, et al. Among authors: bressler nm, bressler sb. Arch Ophthalmol. 2002 Oct;120(10):1307-14. doi: 10.1001/archopht.120.10.1307. Arch Ophthalmol. 2002. PMID: 12365909 Clinical Trial.
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Bressler NM, et al. Among authors: bressler sb. Arch Ophthalmol. 2002 Nov;120(11):1443-54. doi: 10.1001/archopht.120.11.1443. Arch Ophthalmol. 2002. PMID: 12427056 Clinical Trial.
432 results